This is the Company’s second year to be included as one of the Top 100 Companies in Houston
Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced it has been included in the Houston Chronicle’s list of the 100 most successful publicly traded companies in the Houston area.
Castle has been included in the category for Market Value, Market Return & Revenue Growth. This is the second year that Castle has been named in the “CHRON 100” as a top company by the Houston Chronicle. In 2020, the Company received recognition as one of the top initial public offerings of 2019.
“We’re excited to be recognized as one of the top public companies in Houston by the Houston Chronicle again this year,” said Derek Maetzold, president and chief executive officer of Castle Biosciences. “We are proud to be included for our achievements in the category of market value, market return and revenue growth. And we continue to grow our suite of diagnostic and prognostic tests for dermatologic cancers and other dermatologic diseases with unmet clinical need. While DecisionDx ®-Melanoma remains our lead product, in the second half of 2020, we expanded our skin cancer test offerings with the commercial launch of DecisionDx®-SCC for cutaneous squamous cell carcinoma and DecisionDx® DiffDxTM-Melanoma for difficult-to-diagnose melanocytic lesions. In addition, in May of 2021, we acquired a second gene expression profile test for difficult-to-diagnose melanocytic lesions, myPath® Melanoma. We look forward to furthering our position as a leader in providing clinically actionable dermatologic genomic tests designed to transform disease management and help improve the lives of patients.”
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to AI-Techpark.com.
